

Global Cancer Angiogenesis Inhibitors Supply, Demand and Key Producers, 2026-2032

<https://marketpublishers.com/r/G552C89D1871EN.html>

Date: June 2026

Pages: 211

Price: US\$ 4,480.00 (Single User License)

ID: G552C89D1871EN

Abstracts

The global Cancer Angiogenesis Inhibitors market size is expected to reach \$ 21936 million by 2032, rising at a market growth of 8.6% CAGR during the forecast period (2026-2032).

Cancer Angiogenesis Inhibitors are a class of anticancer medicines that inhibit the formation of new tumor blood vessels, impair the function of abnormal tumor vasculature, or block related signaling pathways, thereby reducing the supply of oxygen and nutrients required for tumor growth, invasion, and metastasis. Their common dosage forms include intravenous infusion solutions, lyophilized injectable formulations, and oral tablets or capsules. In terms of structure and composition, the category mainly includes recombinant monoclonal antibodies, fusion proteins, and multi-target small-molecule inhibitors, with primary targets centered on vascular endothelial growth factor, its receptors, and associated angiogenic pathways. This category includes originator innovative drugs as well as commercialized biosimilars and generic small-molecule drugs. It is widely used in the treatment of colorectal cancer, lung cancer, liver cancer, renal cancer, ovarian cancer, cervical cancer, glioblastoma, and selected soft-tissue tumors, and is frequently used in combination with chemotherapy, immunotherapy, or other targeted therapies. Manufacturing generally requires strong capabilities in cell-line development, protein expression and purification, sterile fill-finish, quality consistency control, and, for oral formulations, control of crystal form, impurities, and dissolution performance.

The market for Cancer Angiogenesis Inhibitors remains in an expansion phase, with the most important opportunities coming from the sustained prevalence of solid tumors, longer treatment duration across multiple lines of therapy, and the rising role of combination regimens. These agents are no longer limited to single-agent vascular

suppression; they are increasingly embedded in immunotherapy, chemotherapy, and multi-target treatment strategies, becoming part of integrated management for advanced solid tumors. Product evolution continues across renal cancer, liver cancer, colorectal cancer, and non-small cell lung cancer, spanning traditional antibody products, oral multi-target small molecules, and newer dual-mechanism agents with anti-angiogenic activity. At the same time, the growing availability of biosimilars is expanding patient access and pushing these therapies into broader geographic and economic segments, supporting further growth in treated patient numbers and broader adoption of combination regimens.

The principal restraints in this market come not from lack of clinical interest but from the difficulty of long-term clinical and commercial execution. On the clinical side, this class is associated with safety-management burdens such as hypertension, bleeding, proteinuria, wound-healing complications, and gastrointestinal perforation, which can limit tolerability and duration of treatment for some patients. On the biological side, tumor angiogenesis is not a single-pathway process; alternative pro-angiogenic mechanisms beyond VEGF can produce primary or acquired resistance, reducing long-term efficacy and shortening product advantage. In parallel, patent expiry of major brands has intensified price pressure from biosimilars and generics. While this improves access, it also compresses margins for originators and raises the bar for new entrants in terms of differentiated efficacy, safety, reimbursement access, and global commercialization capability. Competitive advantage is therefore shifting from merely having a product to demonstrating superior clinical value, rational combination strategy, and sustainable cost structure.

Downstream demand is moving away from stand-alone anti-angiogenic use toward a more structured pattern centered on treatment-line positioning, combination therapy, and access optimization. Demand remains concentrated in major oncology hospitals, general hospital oncology centers, and standardized cancer-care networks, with advanced solid tumors still representing the core usage base. However, purchasing and utilization logic is changing: oral small-molecule agents retain strong demand in selected indications because of administration convenience; bevacizumab biosimilars are rapidly replacing part of originator volume in multiple countries and expanding injectable demand into more cost-sensitive markets; and immunotherapy combinations built on anti-angiogenic backbones are moving certain products into earlier and longer treatment settings. Future demand growth is unlikely to be evenly distributed. Instead, it is expected to concentrate in mainstream products that combine clear survival benefit, broad indication coverage, stronger payment support, and stable supply capability.

This report studies the global Cancer Angiogenesis Inhibitors production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Cancer Angiogenesis Inhibitors and provides market size (US\$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Cancer Angiogenesis Inhibitors that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Cancer Angiogenesis Inhibitors total production and demand, 2021-2032, (K Dose)

Global Cancer Angiogenesis Inhibitors total production value, 2021-2032, (USD Million)

Global Cancer Angiogenesis Inhibitors production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Dose), (based on production site)

Global Cancer Angiogenesis Inhibitors consumption by region & country, CAGR, 2021-2032 & (K Dose)

U.S. VS China: Cancer Angiogenesis Inhibitors domestic production, consumption, key domestic manufacturers and share

Global Cancer Angiogenesis Inhibitors production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Dose)

Global Cancer Angiogenesis Inhibitors production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)

Global Cancer Angiogenesis Inhibitors production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)

This report profiles key players in the global Cancer Angiogenesis Inhibitors market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Genentech, Pfizer, Novartis, Takeda, Eli Lilly, Bayer, Eisai, Amgen, Regeneron, Exelixis, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Cancer Angiogenesis Inhibitors market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), volume (production, consumption) & (K Dose) and average price (US\$/Dose) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Cancer Angiogenesis Inhibitors Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Cancer Angiogenesis Inhibitors Market, Segmentation by Type:

VEGF-targeted Therapy

FGF-targeted Therapy

Oncogene-targeted Therapy

Matrix Degradation and Remodeling-targeted Therapy

Others

Global Cancer Angiogenesis Inhibitors Market, Segmentation by Product Origin:

Originator Biologics

Generic Drugs

Global Cancer Angiogenesis Inhibitors Market, Segmentation by Route of Administration:

Intravenous Infusion

Oral Administration

Others

Global Cancer Angiogenesis Inhibitors Market, Segmentation by Target Breadth:

Single-target Agents

Dual-target Agents

Multi-target Agents

Others

Global Cancer Angiogenesis Inhibitors Market, Segmentation by Application:

Cancer

Interferon Alpha-2?

Ocular Neovascularization

Companies Profiled:

Genentech

Pfizer

Novartis

Takeda

Eli Lilly

Bayer

Eisai

Amgen

Regeneron

Exelixis

HUTCHMED

Boehringer Ingelheim

Recordati

Fresenius Kabi

Celltrion

Samsung Bioepis

Biocon Biologics

Amneal

Dr. Reddy's

Intas Pharmaceuticals

Hetero Drugs

Zydus Lifesciences

Reliance Life Sciences

FUJIFILM Kyowa Kirin Biologics

Innovent Biologics

Shanghai Henlius

Qilu Pharmaceutical

Jiangsu Hengrui Medicine

Akeso

Bio-Thera Solutions

Chia Tai Tianqing Pharmaceutical

Key Questions Answered:

1. How big is the global Cancer Angiogenesis Inhibitors market?
2. What is the demand of the global Cancer Angiogenesis Inhibitors market?
3. What is the year over year growth of the global Cancer Angiogenesis Inhibitors market?
4. What is the production and production value of the global Cancer Angiogenesis Inhibitors market?
5. Who are the key producers in the global Cancer Angiogenesis Inhibitors market?
6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

- 1.1 Cancer Angiogenesis Inhibitors Introduction
- 1.2 World Cancer Angiogenesis Inhibitors Supply & Forecast
 - 1.2.1 World Cancer Angiogenesis Inhibitors Production Value (2021 & 2025 & 2032)
 - 1.2.2 World Cancer Angiogenesis Inhibitors Production (2021-2032)
 - 1.2.3 World Cancer Angiogenesis Inhibitors Pricing Trends (2021-2032)
- 1.3 World Cancer Angiogenesis Inhibitors Production by Region (Based on Production Site)
 - 1.3.1 World Cancer Angiogenesis Inhibitors Production Value by Region (2021-2032)
 - 1.3.2 World Cancer Angiogenesis Inhibitors Production by Region (2021-2032)
 - 1.3.3 World Cancer Angiogenesis Inhibitors Average Price by Region (2021-2032)
 - 1.3.4 North America Cancer Angiogenesis Inhibitors Production (2021-2032)
 - 1.3.5 Europe Cancer Angiogenesis Inhibitors Production (2021-2032)
 - 1.3.6 China Cancer Angiogenesis Inhibitors Production (2021-2032)
 - 1.3.7 Japan Cancer Angiogenesis Inhibitors Production (2021-2032)
 - 1.3.8 India Cancer Angiogenesis Inhibitors Production (2021-2032)
 - 1.3.9 South Korea Cancer Angiogenesis Inhibitors Production (2021-2032)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 Cancer Angiogenesis Inhibitors Market Drivers
 - 1.4.2 Factors Affecting Demand
 - 1.4.3 Cancer Angiogenesis Inhibitors Major Market Trends

2 DEMAND SUMMARY

- 2.1 World Cancer Angiogenesis Inhibitors Demand (2021-2032)
- 2.2 World Cancer Angiogenesis Inhibitors Consumption by Region
 - 2.2.1 World Cancer Angiogenesis Inhibitors Consumption by Region (2021-2026)
 - 2.2.2 World Cancer Angiogenesis Inhibitors Consumption Forecast by Region (2027-2032)
- 2.3 United States Cancer Angiogenesis Inhibitors Consumption (2021-2032)
- 2.4 China Cancer Angiogenesis Inhibitors Consumption (2021-2032)
- 2.5 Europe Cancer Angiogenesis Inhibitors Consumption (2021-2032)
- 2.6 Japan Cancer Angiogenesis Inhibitors Consumption (2021-2032)
- 2.7 South Korea Cancer Angiogenesis Inhibitors Consumption (2021-2032)
- 2.8 ASEAN Cancer Angiogenesis Inhibitors Consumption (2021-2032)
- 2.9 India Cancer Angiogenesis Inhibitors Consumption (2021-2032)

3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS

- 3.1 World Cancer Angiogenesis Inhibitors Production Value by Manufacturer (2021-2026)
- 3.2 World Cancer Angiogenesis Inhibitors Production by Manufacturer (2021-2026)
- 3.3 World Cancer Angiogenesis Inhibitors Average Price by Manufacturer (2021-2026)
- 3.4 Cancer Angiogenesis Inhibitors Company Evaluation Quadrant
- 3.5 Industry Rank and Concentration Rate (CR)
 - 3.5.1 Global Cancer Angiogenesis Inhibitors Industry Rank of Major Manufacturers
 - 3.5.2 Global Concentration Ratios (CR4) for Cancer Angiogenesis Inhibitors in 2025
 - 3.5.3 Global Concentration Ratios (CR8) for Cancer Angiogenesis Inhibitors in 2025
- 3.6 Cancer Angiogenesis Inhibitors Market: Overall Company Footprint Analysis
 - 3.6.1 Cancer Angiogenesis Inhibitors Market: Region Footprint
 - 3.6.2 Cancer Angiogenesis Inhibitors Market: Company Product Type Footprint
 - 3.6.3 Cancer Angiogenesis Inhibitors Market: Company Product Application Footprint
- 3.7 Competitive Environment
 - 3.7.1 Historical Structure of the Industry
 - 3.7.2 Barriers of Market Entry
 - 3.7.3 Factors of Competition
- 3.8 New Entrant and Capacity Expansion Plans
- 3.9 Mergers, Acquisition, Agreements, and Collaborations

4 UNITED STATES VS CHINA VS REST OF THE WORLD

- 4.1 United States VS China: Cancer Angiogenesis Inhibitors Production Value Comparison
 - 4.1.1 United States VS China: Cancer Angiogenesis Inhibitors Production Value Comparison (2021 & 2025 & 2032)
 - 4.1.2 United States VS China: Cancer Angiogenesis Inhibitors Production Value Market Share Comparison (2021 & 2025 & 2032)
- 4.2 United States VS China: Cancer Angiogenesis Inhibitors Production Comparison
 - 4.2.1 United States VS China: Cancer Angiogenesis Inhibitors Production Comparison (2021 & 2025 & 2032)
 - 4.2.2 United States VS China: Cancer Angiogenesis Inhibitors Production Market Share Comparison (2021 & 2025 & 2032)
- 4.3 United States VS China: Cancer Angiogenesis Inhibitors Consumption Comparison
 - 4.3.1 United States VS China: Cancer Angiogenesis Inhibitors Consumption Comparison (2021 & 2025 & 2032)

4.3.2 United States VS China: Cancer Angiogenesis Inhibitors Consumption Market Share Comparison (2021 & 2025 & 2032)

4.4 United States Based Cancer Angiogenesis Inhibitors Manufacturers and Market Share, 2021-2026

4.4.1 United States Based Cancer Angiogenesis Inhibitors Manufacturers, Headquarters and Production Site (States, Country)

4.4.2 United States Based Manufacturers Cancer Angiogenesis Inhibitors Production Value (2021-2026)

4.4.3 United States Based Manufacturers Cancer Angiogenesis Inhibitors Production (2021-2026)

4.5 China Based Cancer Angiogenesis Inhibitors Manufacturers and Market Share

4.5.1 China Based Cancer Angiogenesis Inhibitors Manufacturers, Headquarters and Production Site (Province, Country)

4.5.2 China Based Manufacturers Cancer Angiogenesis Inhibitors Production Value (2021-2026)

4.5.3 China Based Manufacturers Cancer Angiogenesis Inhibitors Production (2021-2026)

4.6 Rest of World Based Cancer Angiogenesis Inhibitors Manufacturers and Market Share, 2021-2026

4.6.1 Rest of World Based Cancer Angiogenesis Inhibitors Manufacturers, Headquarters and Production Site (State, Country)

4.6.2 Rest of World Based Manufacturers Cancer Angiogenesis Inhibitors Production Value (2021-2026)

4.6.3 Rest of World Based Manufacturers Cancer Angiogenesis Inhibitors Production (2021-2026)

5 MARKET ANALYSIS BY TYPE

5.1 World Cancer Angiogenesis Inhibitors Market Size Overview by Type: 2021 VS 2025 VS 2032

5.2 Segment Introduction by Type

5.2.1 VEGF-targeted Therapy

5.2.2 FGF-targeted Therapy

5.2.3 Oncogene-targeted Therapy

5.2.4 Matrix Degradation and Remodeling-targeted Therapy

5.2.5 Others

5.3 Market Segment by Type

5.3.1 World Cancer Angiogenesis Inhibitors Production by Type (2021-2032)

5.3.2 World Cancer Angiogenesis Inhibitors Production Value by Type (2021-2032)

5.3.3 World Cancer Angiogenesis Inhibitors Average Price by Type (2021-2032)

6 MARKET ANALYSIS BY PRODUCT ORIGIN

6.1 World Cancer Angiogenesis Inhibitors Market Size Overview by Product Origin: 2021 VS 2025 VS 2032

6.2 Segment Introduction by Product Origin

6.2.1 Originator Biologics

6.2.2 Generic Drugs

6.3 Market Segment by Product Origin

6.3.1 World Cancer Angiogenesis Inhibitors Production by Product Origin (2021-2032)

6.3.2 World Cancer Angiogenesis Inhibitors Production Value by Product Origin (2021-2032)

6.3.3 World Cancer Angiogenesis Inhibitors Average Price by Product Origin (2021-2032)

7 MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

7.1 World Cancer Angiogenesis Inhibitors Market Size Overview by Route of Administration: 2021 VS 2025 VS 2032

7.2 Segment Introduction by Route of Administration

7.2.1 Intravenous Infusion

7.2.2 Oral Administration

7.2.3 Others

7.3 Market Segment by Route of Administration

7.3.1 World Cancer Angiogenesis Inhibitors Production by Route of Administration (2021-2032)

7.3.2 World Cancer Angiogenesis Inhibitors Production Value by Route of Administration (2021-2032)

7.3.3 World Cancer Angiogenesis Inhibitors Average Price by Route of Administration (2021-2032)

8 MARKET ANALYSIS BY TARGET BREADTH

8.1 World Cancer Angiogenesis Inhibitors Market Size Overview by Target Breadth: 2021 VS 2025 VS 2032

8.2 Segment Introduction by Target Breadth

8.2.1 Single-target Agents

8.2.2 Dual-target Agents

8.2.3 Multi-target Agents

8.2.4 Others

8.3 Market Segment by Target Breadth

8.3.1 World Cancer Angiogenesis Inhibitors Production by Target Breadth (2021-2032)

8.3.2 World Cancer Angiogenesis Inhibitors Production Value by Target Breadth (2021-2032)

8.3.3 World Cancer Angiogenesis Inhibitors Average Price by Target Breadth (2021-2032)

9 MARKET ANALYSIS BY APPLICATION

9.1 World Cancer Angiogenesis Inhibitors Market Size Overview by Application: 2021 VS 2025 VS 2032

9.2 Segment Introduction by Application

9.2.1 Cancer

9.2.2 Interferon Alpha-2?

9.2.3 Ocular Neovascularization

9.3 Market Segment by Application

9.3.1 World Cancer Angiogenesis Inhibitors Production by Application (2021-2032)

9.3.2 World Cancer Angiogenesis Inhibitors Production Value by Application (2021-2032)

9.3.3 World Cancer Angiogenesis Inhibitors Average Price by Application (2021-2032)

10 COMPANY PROFILES

10.1 Genentech

10.1.1 Genentech Details

10.1.2 Genentech Major Business

10.1.3 Genentech Cancer Angiogenesis Inhibitors Product and Services

10.1.4 Genentech Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and Market Share (2021-2026)

10.1.5 Genentech Recent Developments/Updates

10.1.6 Genentech Competitive Strengths & Weaknesses

10.2 Pfizer

10.2.1 Pfizer Details

10.2.2 Pfizer Major Business

10.2.3 Pfizer Cancer Angiogenesis Inhibitors Product and Services

10.2.4 Pfizer Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and Market Share (2021-2026)

- 10.2.5 Pfizer Recent Developments/Updates
- 10.2.6 Pfizer Competitive Strengths & Weaknesses
- 10.3 Novartis
 - 10.3.1 Novartis Details
 - 10.3.2 Novartis Major Business
 - 10.3.3 Novartis Cancer Angiogenesis Inhibitors Product and Services
 - 10.3.4 Novartis Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and Market Share (2021-2026)
 - 10.3.5 Novartis Recent Developments/Updates
 - 10.3.6 Novartis Competitive Strengths & Weaknesses
- 10.4 Takeda
 - 10.4.1 Takeda Details
 - 10.4.2 Takeda Major Business
 - 10.4.3 Takeda Cancer Angiogenesis Inhibitors Product and Services
 - 10.4.4 Takeda Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and Market Share (2021-2026)
 - 10.4.5 Takeda Recent Developments/Updates
 - 10.4.6 Takeda Competitive Strengths & Weaknesses
- 10.5 Eli Lilly
 - 10.5.1 Eli Lilly Details
 - 10.5.2 Eli Lilly Major Business
 - 10.5.3 Eli Lilly Cancer Angiogenesis Inhibitors Product and Services
 - 10.5.4 Eli Lilly Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and Market Share (2021-2026)
 - 10.5.5 Eli Lilly Recent Developments/Updates
 - 10.5.6 Eli Lilly Competitive Strengths & Weaknesses
- 10.6 Bayer
 - 10.6.1 Bayer Details
 - 10.6.2 Bayer Major Business
 - 10.6.3 Bayer Cancer Angiogenesis Inhibitors Product and Services
 - 10.6.4 Bayer Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and Market Share (2021-2026)
 - 10.6.5 Bayer Recent Developments/Updates
 - 10.6.6 Bayer Competitive Strengths & Weaknesses
- 10.7 Eisai
 - 10.7.1 Eisai Details
 - 10.7.2 Eisai Major Business
 - 10.7.3 Eisai Cancer Angiogenesis Inhibitors Product and Services
 - 10.7.4 Eisai Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and

Market Share (2021-2026)

10.7.5 Eisai Recent Developments/Updates

10.7.6 Eisai Competitive Strengths & Weaknesses

10.8 Amgen

10.8.1 Amgen Details

10.8.2 Amgen Major Business

10.8.3 Amgen Cancer Angiogenesis Inhibitors Product and Services

10.8.4 Amgen Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and Market Share (2021-2026)

10.8.5 Amgen Recent Developments/Updates

10.8.6 Amgen Competitive Strengths & Weaknesses

10.9 Regeneron

10.9.1 Regeneron Details

10.9.2 Regeneron Major Business

10.9.3 Regeneron Cancer Angiogenesis Inhibitors Product and Services

10.9.4 Regeneron Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and Market Share (2021-2026)

10.9.5 Regeneron Recent Developments/Updates

10.9.6 Regeneron Competitive Strengths & Weaknesses

10.10 Exelixis

10.10.1 Exelixis Details

10.10.2 Exelixis Major Business

10.10.3 Exelixis Cancer Angiogenesis Inhibitors Product and Services

10.10.4 Exelixis Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and Market Share (2021-2026)

10.10.5 Exelixis Recent Developments/Updates

10.10.6 Exelixis Competitive Strengths & Weaknesses

10.11 HUTCHMED

10.11.1 HUTCHMED Details

10.11.2 HUTCHMED Major Business

10.11.3 HUTCHMED Cancer Angiogenesis Inhibitors Product and Services

10.11.4 HUTCHMED Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and Market Share (2021-2026)

10.11.5 HUTCHMED Recent Developments/Updates

10.11.6 HUTCHMED Competitive Strengths & Weaknesses

10.12 Boehringer Ingelheim

10.12.1 Boehringer Ingelheim Details

10.12.2 Boehringer Ingelheim Major Business

10.12.3 Boehringer Ingelheim Cancer Angiogenesis Inhibitors Product and Services

- 10.12.4 Boehringer Ingelheim Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and Market Share (2021-2026)
- 10.12.5 Boehringer Ingelheim Recent Developments/Updates
- 10.12.6 Boehringer Ingelheim Competitive Strengths & Weaknesses
- 10.13 Recordati
 - 10.13.1 Recordati Details
 - 10.13.2 Recordati Major Business
 - 10.13.3 Recordati Cancer Angiogenesis Inhibitors Product and Services
 - 10.13.4 Recordati Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and Market Share (2021-2026)
 - 10.13.5 Recordati Recent Developments/Updates
 - 10.13.6 Recordati Competitive Strengths & Weaknesses
- 10.14 Fresenius Kabi
 - 10.14.1 Fresenius Kabi Details
 - 10.14.2 Fresenius Kabi Major Business
 - 10.14.3 Fresenius Kabi Cancer Angiogenesis Inhibitors Product and Services
 - 10.14.4 Fresenius Kabi Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and Market Share (2021-2026)
 - 10.14.5 Fresenius Kabi Recent Developments/Updates
 - 10.14.6 Fresenius Kabi Competitive Strengths & Weaknesses
- 10.15 Celltrion
 - 10.15.1 Celltrion Details
 - 10.15.2 Celltrion Major Business
 - 10.15.3 Celltrion Cancer Angiogenesis Inhibitors Product and Services
 - 10.15.4 Celltrion Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and Market Share (2021-2026)
 - 10.15.5 Celltrion Recent Developments/Updates
 - 10.15.6 Celltrion Competitive Strengths & Weaknesses
- 10.16 Samsung Bioepis
 - 10.16.1 Samsung Bioepis Details
 - 10.16.2 Samsung Bioepis Major Business
 - 10.16.3 Samsung Bioepis Cancer Angiogenesis Inhibitors Product and Services
 - 10.16.4 Samsung Bioepis Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and Market Share (2021-2026)
 - 10.16.5 Samsung Bioepis Recent Developments/Updates
 - 10.16.6 Samsung Bioepis Competitive Strengths & Weaknesses
- 10.17 Biocon Biologics
 - 10.17.1 Biocon Biologics Details
 - 10.17.2 Biocon Biologics Major Business

- 10.17.3 Biocon Biologics Cancer Angiogenesis Inhibitors Product and Services
- 10.17.4 Biocon Biologics Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and Market Share (2021-2026)
- 10.17.5 Biocon Biologics Recent Developments/Updates
- 10.17.6 Biocon Biologics Competitive Strengths & Weaknesses
- 10.18 Amneal
 - 10.18.1 Amneal Details
 - 10.18.2 Amneal Major Business
 - 10.18.3 Amneal Cancer Angiogenesis Inhibitors Product and Services
 - 10.18.4 Amneal Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and Market Share (2021-2026)
 - 10.18.5 Amneal Recent Developments/Updates
 - 10.18.6 Amneal Competitive Strengths & Weaknesses
- 10.19 Dr. Reddy's
 - 10.19.1 Dr. Reddy's Details
 - 10.19.2 Dr. Reddy's Major Business
 - 10.19.3 Dr. Reddy's Cancer Angiogenesis Inhibitors Product and Services
 - 10.19.4 Dr. Reddy's Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and Market Share (2021-2026)
 - 10.19.5 Dr. Reddy's Recent Developments/Updates
 - 10.19.6 Dr. Reddy's Competitive Strengths & Weaknesses
- 10.20 Intas Pharmaceuticals
 - 10.20.1 Intas Pharmaceuticals Details
 - 10.20.2 Intas Pharmaceuticals Major Business
 - 10.20.3 Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Product and Services
 - 10.20.4 Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and Market Share (2021-2026)
 - 10.20.5 Intas Pharmaceuticals Recent Developments/Updates
 - 10.20.6 Intas Pharmaceuticals Competitive Strengths & Weaknesses
- 10.21 Hetero Drugs
 - 10.21.1 Hetero Drugs Details
 - 10.21.2 Hetero Drugs Major Business
 - 10.21.3 Hetero Drugs Cancer Angiogenesis Inhibitors Product and Services
 - 10.21.4 Hetero Drugs Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and Market Share (2021-2026)
 - 10.21.5 Hetero Drugs Recent Developments/Updates
 - 10.21.6 Hetero Drugs Competitive Strengths & Weaknesses
- 10.22 Zydus Lifesciences
 - 10.22.1 Zydus Lifesciences Details

- 10.22.2 Zydus Lifesciences Major Business
- 10.22.3 Zydus Lifesciences Cancer Angiogenesis Inhibitors Product and Services
- 10.22.4 Zydus Lifesciences Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and Market Share (2021-2026)
- 10.22.5 Zydus Lifesciences Recent Developments/Updates
- 10.22.6 Zydus Lifesciences Competitive Strengths & Weaknesses
- 10.23 Reliance Life Sciences
 - 10.23.1 Reliance Life Sciences Details
 - 10.23.2 Reliance Life Sciences Major Business
 - 10.23.3 Reliance Life Sciences Cancer Angiogenesis Inhibitors Product and Services
 - 10.23.4 Reliance Life Sciences Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and Market Share (2021-2026)
 - 10.23.5 Reliance Life Sciences Recent Developments/Updates
 - 10.23.6 Reliance Life Sciences Competitive Strengths & Weaknesses
- 10.24 FUJIFILM Kyowa Kirin Biologics
 - 10.24.1 FUJIFILM Kyowa Kirin Biologics Details
 - 10.24.2 FUJIFILM Kyowa Kirin Biologics Major Business
 - 10.24.3 FUJIFILM Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Product and Services
 - 10.24.4 FUJIFILM Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and Market Share (2021-2026)
 - 10.24.5 FUJIFILM Kyowa Kirin Biologics Recent Developments/Updates
 - 10.24.6 FUJIFILM Kyowa Kirin Biologics Competitive Strengths & Weaknesses
- 10.25 Innovent Biologics
 - 10.25.1 Innovent Biologics Details
 - 10.25.2 Innovent Biologics Major Business
 - 10.25.3 Innovent Biologics Cancer Angiogenesis Inhibitors Product and Services
 - 10.25.4 Innovent Biologics Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and Market Share (2021-2026)
 - 10.25.5 Innovent Biologics Recent Developments/Updates
 - 10.25.6 Innovent Biologics Competitive Strengths & Weaknesses
- 10.26 Shanghai Henlius
 - 10.26.1 Shanghai Henlius Details
 - 10.26.2 Shanghai Henlius Major Business
 - 10.26.3 Shanghai Henlius Cancer Angiogenesis Inhibitors Product and Services
 - 10.26.4 Shanghai Henlius Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and Market Share (2021-2026)
 - 10.26.5 Shanghai Henlius Recent Developments/Updates
 - 10.26.6 Shanghai Henlius Competitive Strengths & Weaknesses

10.27 Qilu Pharmaceutical

10.27.1 Qilu Pharmaceutical Details

10.27.2 Qilu Pharmaceutical Major Business

10.27.3 Qilu Pharmaceutical Cancer Angiogenesis Inhibitors Product and Services

10.27.4 Qilu Pharmaceutical Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and Market Share (2021-2026)

10.27.5 Qilu Pharmaceutical Recent Developments/Updates

10.27.6 Qilu Pharmaceutical Competitive Strengths & Weaknesses

10.28 Jiangsu Hengrui Medicine

10.28.1 Jiangsu Hengrui Medicine Details

10.28.2 Jiangsu Hengrui Medicine Major Business

10.28.3 Jiangsu Hengrui Medicine Cancer Angiogenesis Inhibitors Product and Services

10.28.4 Jiangsu Hengrui Medicine Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and Market Share (2021-2026)

10.28.5 Jiangsu Hengrui Medicine Recent Developments/Updates

10.28.6 Jiangsu Hengrui Medicine Competitive Strengths & Weaknesses

10.29 Akeso

10.29.1 Akeso Details

10.29.2 Akeso Major Business

10.29.3 Akeso Cancer Angiogenesis Inhibitors Product and Services

10.29.4 Akeso Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and Market Share (2021-2026)

10.29.5 Akeso Recent Developments/Updates

10.29.6 Akeso Competitive Strengths & Weaknesses

10.30 Bio-Thera Solutions

10.30.1 Bio-Thera Solutions Details

10.30.2 Bio-Thera Solutions Major Business

10.30.3 Bio-Thera Solutions Cancer Angiogenesis Inhibitors Product and Services

10.30.4 Bio-Thera Solutions Cancer Angiogenesis Inhibitors Production, Price, Value, Gross Margin and Market Share (2021-2026)

10.30.5 Bio-Thera Solutions Recent Developments/Updates

10.30.6 Bio-Thera Solutions Competitive Strengths & Weaknesses

10.31 Chia Tai Tianqing Pharmaceutical

10.31.1 Chia Tai Tianqing Pharmaceutical Details

10.31.2 Chia Tai Tianqing Pharmaceutical Major Business

10.31.3 Chia Tai Tianqing Pharmaceutical Cancer Angiogenesis Inhibitors Product and Services

10.31.4 Chia Tai Tianqing Pharmaceutical Cancer Angiogenesis Inhibitors Production,

Price, Value, Gross Margin and Market Share (2021-2026)

10.31.5 Chia Tai Tianqing Pharmaceutical Recent Developments/Updates

10.31.6 Chia Tai Tianqing Pharmaceutical Competitive Strengths & Weaknesses

11 INDUSTRY CHAIN ANALYSIS

11.1 Cancer Angiogenesis Inhibitors Industry Chain

11.2 Cancer Angiogenesis Inhibitors Upstream Analysis

11.2.1 Cancer Angiogenesis Inhibitors Core Raw Materials

11.2.2 Main Manufacturers of Cancer Angiogenesis Inhibitors Core Raw Materials

11.3 Midstream Analysis

11.4 Downstream Analysis

11.5 Cancer Angiogenesis Inhibitors Production Mode

11.6 Cancer Angiogenesis Inhibitors Procurement Model

11.7 Cancer Angiogenesis Inhibitors Industry Sales Model and Sales Channels

11.7.1 Cancer Angiogenesis Inhibitors Sales Model

11.7.2 Cancer Angiogenesis Inhibitors Typical Distributors

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology

13.2 Research Process and Data Source

13.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World Cancer Angiogenesis Inhibitors Production Value by Region (2021, 2025 and 2032) & (USD Million)

Table 2. World Cancer Angiogenesis Inhibitors Production Value by Region (2021-2026) & (USD Million)

Table 3. World Cancer Angiogenesis Inhibitors Production Value by Region (2027-2032) & (USD Million)

Table 4. World Cancer Angiogenesis Inhibitors Production Value Market Share by Region (2021-2026)

Table 5. World Cancer Angiogenesis Inhibitors Production Value Market Share by Region (2027-2032)

Table 6. World Cancer Angiogenesis Inhibitors Production by Region (2021-2026) & (K Dose)

Table 7. World Cancer Angiogenesis Inhibitors Production by Region (2027-2032) & (K Dose)

Table 8. World Cancer Angiogenesis Inhibitors Production Market Share by Region (2021-2026)

Table 9. World Cancer Angiogenesis Inhibitors Production Market Share by Region (2027-2032)

Table 10. World Cancer Angiogenesis Inhibitors Average Price by Region (2021-2026) & (US\$/Dose)

Table 11. World Cancer Angiogenesis Inhibitors Average Price by Region (2027-2032) & (US\$/Dose)

Table 12. Cancer Angiogenesis Inhibitors Major Market Trends

Table 13. World Cancer Angiogenesis Inhibitors Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Dose)

Table 14. World Cancer Angiogenesis Inhibitors Consumption by Region (2021-2026) & (K Dose)

Table 15. World Cancer Angiogenesis Inhibitors Consumption Forecast by Region (2027-2032) & (K Dose)

Table 16. World Cancer Angiogenesis Inhibitors Production Value by Manufacturer (2021-2026) & (USD Million)

Table 17. Production Value Market Share of Key Cancer Angiogenesis Inhibitors Producers in 2025

Table 18. World Cancer Angiogenesis Inhibitors Production by Manufacturer (2021-2026) & (K Dose)

Table 19. Production Market Share of Key Cancer Angiogenesis Inhibitors Producers in 2025

Table 20. World Cancer Angiogenesis Inhibitors Average Price by Manufacturer (2021-2026) & (US\$/Dose)

Table 21. Global Cancer Angiogenesis Inhibitors Company Evaluation Quadrant

Table 22. World Cancer Angiogenesis Inhibitors Industry Rank of Major Manufacturers, Based on Production Value in 2025

Table 23. Head Office and Cancer Angiogenesis Inhibitors Production Site of Key Manufacturer

Table 24. Cancer Angiogenesis Inhibitors Market: Company Product Type Footprint

Table 25. Cancer Angiogenesis Inhibitors Market: Company Product Application Footprint

Table 26. Cancer Angiogenesis Inhibitors Competitive Factors

Table 27. Cancer Angiogenesis Inhibitors New Entrant and Capacity Expansion Plans

Table 28. Cancer Angiogenesis Inhibitors Mergers & Acquisitions Activity

Table 29. United States VS China Cancer Angiogenesis Inhibitors Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)

Table 30. United States VS China Cancer Angiogenesis Inhibitors Production Comparison, (2021 & 2025 & 2032) & (K Dose)

Table 31. United States VS China Cancer Angiogenesis Inhibitors Consumption Comparison, (2021 & 2025 & 2032) & (K Dose)

Table 32. United States Based Cancer Angiogenesis Inhibitors Manufacturers, Headquarters and Production Site (States, Country)

Table 33. United States Based Manufacturers Cancer Angiogenesis Inhibitors Production Value, (2021-2026) & (USD Million)

Table 34. United States Based Manufacturers Cancer Angiogenesis Inhibitors Production Value Market Share (2021-2026)

Table 35. United States Based Manufacturers Cancer Angiogenesis Inhibitors Production (2021-2026) & (K Dose)

Table 36. United States Based Manufacturers Cancer Angiogenesis Inhibitors Production Market Share (2021-2026)

Table 37. China Based Cancer Angiogenesis Inhibitors Manufacturers, Headquarters and Production Site (Province, Country)

Table 38. China Based Manufacturers Cancer Angiogenesis Inhibitors Production Value, (2021-2026) & (USD Million)

Table 39. China Based Manufacturers Cancer Angiogenesis Inhibitors Production Value Market Share (2021-2026)

Table 40. China Based Manufacturers Cancer Angiogenesis Inhibitors Production, (2021-2026) & (K Dose)

Table 41. China Based Manufacturers Cancer Angiogenesis Inhibitors Production Market Share (2021-2026)

Table 42. Rest of World Based Cancer Angiogenesis Inhibitors Manufacturers, Headquarters and Production Site (State, Country)

Table 43. Rest of World Based Manufacturers Cancer Angiogenesis Inhibitors Production Value, (2021-2026) & (USD Million)

Table 44. Rest of World Based Manufacturers Cancer Angiogenesis Inhibitors Production Value Market Share (2021-2026)

Table 45. Rest of World Based Manufacturers Cancer Angiogenesis Inhibitors Production, (2021-2026) & (K Dose)

Table 46. Rest of World Based Manufacturers Cancer Angiogenesis Inhibitors Production Market Share (2021-2026)

Table 47. World Cancer Angiogenesis Inhibitors Production Value by Type, (USD Million), 2021 & 2025 & 2032

Table 48. World Cancer Angiogenesis Inhibitors Production by Type (2021-2026) & (K Dose)

Table 49. World Cancer Angiogenesis Inhibitors Production by Type (2027-2032) & (K Dose)

Table 50. World Cancer Angiogenesis Inhibitors Production Value by Type (2021-2026) & (USD Million)

Table 51. World Cancer Angiogenesis Inhibitors Production Value by Type (2027-2032) & (USD Million)

Table 52. World Cancer Angiogenesis Inhibitors Average Price by Type (2021-2026) & (US\$/Dose)

Table 53. World Cancer Angiogenesis Inhibitors Average Price by Type (2027-2032) & (US\$/Dose)

Table 54. World Cancer Angiogenesis Inhibitors Production Value by Product Origin, (USD Million), 2021 & 2025 & 2032

Table 55. World Cancer Angiogenesis Inhibitors Production by Product Origin (2021-2026) & (K Dose)

Table 56. World Cancer Angiogenesis Inhibitors Production by Product Origin (2027-2032) & (K Dose)

Table 57. World Cancer Angiogenesis Inhibitors Production Value by Product Origin (2021-2026) & (USD Million)

Table 58. World Cancer Angiogenesis Inhibitors Production Value by Product Origin (2027-2032) & (USD Million)

Table 59. World Cancer Angiogenesis Inhibitors Average Price by Product Origin (2021-2026) & (US\$/Dose)

Table 60. World Cancer Angiogenesis Inhibitors Average Price by Product Origin

(2027-2032) & (US\$/Dose)

Table 61. World Cancer Angiogenesis Inhibitors Production Value by Route of Administration, (USD Million), 2021 & 2025 & 2032

Table 62. World Cancer Angiogenesis Inhibitors Production by Route of Administration (2021-2026) & (K Dose)

Table 63. World Cancer Angiogenesis Inhibitors Production by Route of Administration (2027-2032) & (K Dose)

Table 64. World Cancer Angiogenesis Inhibitors Production Value by Route of Administration (2021-2026) & (USD Million)

Table 65. World Cancer Angiogenesis Inhibitors Production Value by Route of Administration (2027-2032) & (USD Million)

Table 66. World Cancer Angiogenesis Inhibitors Average Price by Route of Administration (2021-2026) & (US\$/Dose)

Table 67. World Cancer Angiogenesis Inhibitors Average Price by Route of Administration (2027-2032) & (US\$/Dose)

Table 68. World Cancer Angiogenesis Inhibitors Production Value by Target Breadth, (USD Million), 2021 & 2025 & 2032

Table 69. World Cancer Angiogenesis Inhibitors Production by Target Breadth (2021-2026) & (K Dose)

Table 70. World Cancer Angiogenesis Inhibitors Production by Target Breadth (2027-2032) & (K Dose)

Table 71. World Cancer Angiogenesis Inhibitors Production Value by Target Breadth (2021-2026) & (USD Million)

Table 72. World Cancer Angiogenesis Inhibitors Production Value by Target Breadth (2027-2032) & (USD Million)

Table 73. World Cancer Angiogenesis Inhibitors Average Price by Target Breadth (2021-2026) & (US\$/Dose)

Table 74. World Cancer Angiogenesis Inhibitors Average Price by Target Breadth (2027-2032) & (US\$/Dose)

Table 75. World Cancer Angiogenesis Inhibitors Production Value by Application, (USD Million), 2021 & 2025 & 2032

Table 76. World Cancer Angiogenesis Inhibitors Production by Application (2021-2026) & (K Dose)

Table 77. World Cancer Angiogenesis Inhibitors Production by Application (2027-2032) & (K Dose)

Table 78. World Cancer Angiogenesis Inhibitors Production Value by Application (2021-2026) & (USD Million)

Table 79. World Cancer Angiogenesis Inhibitors Production Value by Application (2027-2032) & (USD Million)

Table 80. World Cancer Angiogenesis Inhibitors Average Price by Application (2021-2026) & (US\$/Dose)

Table 81. World Cancer Angiogenesis Inhibitors Average Price by Application (2027-2032) & (US\$/Dose)

Table 82. Genentech Basic Information, Manufacturing Base and Competitors

Table 83. Genentech Major Business

Table 84. Genentech Cancer Angiogenesis Inhibitors Product and Services

Table 85. Genentech Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 86. Genentech Recent Developments/Updates

Table 87. Genentech Competitive Strengths & Weaknesses

Table 88. Pfizer Basic Information, Manufacturing Base and Competitors

Table 89. Pfizer Major Business

Table 90. Pfizer Cancer Angiogenesis Inhibitors Product and Services

Table 91. Pfizer Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 92. Pfizer Recent Developments/Updates

Table 93. Pfizer Competitive Strengths & Weaknesses

Table 94. Novartis Basic Information, Manufacturing Base and Competitors

Table 95. Novartis Major Business

Table 96. Novartis Cancer Angiogenesis Inhibitors Product and Services

Table 97. Novartis Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 98. Novartis Recent Developments/Updates

Table 99. Novartis Competitive Strengths & Weaknesses

Table 100. Takeda Basic Information, Manufacturing Base and Competitors

Table 101. Takeda Major Business

Table 102. Takeda Cancer Angiogenesis Inhibitors Product and Services

Table 103. Takeda Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 104. Takeda Recent Developments/Updates

Table 105. Takeda Competitive Strengths & Weaknesses

Table 106. Eli Lilly Basic Information, Manufacturing Base and Competitors

Table 107. Eli Lilly Major Business

Table 108. Eli Lilly Cancer Angiogenesis Inhibitors Product and Services

Table 109. Eli Lilly Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 110. Eli Lilly Recent Developments/Updates

Table 111. Eli Lilly Competitive Strengths & Weaknesses

Table 112. Bayer Basic Information, Manufacturing Base and Competitors

Table 113. Bayer Major Business

Table 114. Bayer Cancer Angiogenesis Inhibitors Product and Services

Table 115. Bayer Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 116. Bayer Recent Developments/Updates

Table 117. Bayer Competitive Strengths & Weaknesses

Table 118. Eisai Basic Information, Manufacturing Base and Competitors

Table 119. Eisai Major Business

Table 120. Eisai Cancer Angiogenesis Inhibitors Product and Services

Table 121. Eisai Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 122. Eisai Recent Developments/Updates

Table 123. Eisai Competitive Strengths & Weaknesses

Table 124. Amgen Basic Information, Manufacturing Base and Competitors

Table 125. Amgen Major Business

Table 126. Amgen Cancer Angiogenesis Inhibitors Product and Services

Table 127. Amgen Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 128. Amgen Recent Developments/Updates

Table 129. Amgen Competitive Strengths & Weaknesses

Table 130. Regeneron Basic Information, Manufacturing Base and Competitors

Table 131. Regeneron Major Business

Table 132. Regeneron Cancer Angiogenesis Inhibitors Product and Services

Table 133. Regeneron Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 134. Regeneron Recent Developments/Updates

Table 135. Regeneron Competitive Strengths & Weaknesses

Table 136. Exelixis Basic Information, Manufacturing Base and Competitors

Table 137. Exelixis Major Business

Table 138. Exelixis Cancer Angiogenesis Inhibitors Product and Services

Table 139. Exelixis Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 140. Exelixis Recent Developments/Updates

Table 141. Exelixis Competitive Strengths & Weaknesses

Table 142. HUTCHMED Basic Information, Manufacturing Base and Competitors

Table 143. HUTCHMED Major Business

Table 144. HUTCHMED Cancer Angiogenesis Inhibitors Product and Services

Table 145. HUTCHMED Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 146. HUTCHMED Recent Developments/Updates

Table 147. HUTCHMED Competitive Strengths & Weaknesses

Table 148. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors

Table 149. Boehringer Ingelheim Major Business

Table 150. Boehringer Ingelheim Cancer Angiogenesis Inhibitors Product and Services

Table 151. Boehringer Ingelheim Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 152. Boehringer Ingelheim Recent Developments/Updates

Table 153. Boehringer Ingelheim Competitive Strengths & Weaknesses

Table 154. Recordati Basic Information, Manufacturing Base and Competitors

Table 155. Recordati Major Business

Table 156. Recordati Cancer Angiogenesis Inhibitors Product and Services

Table 157. Recordati Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 158. Recordati Recent Developments/Updates

Table 159. Recordati Competitive Strengths & Weaknesses

Table 160. Fresenius Kabi Basic Information, Manufacturing Base and Competitors

Table 161. Fresenius Kabi Major Business

Table 162. Fresenius Kabi Cancer Angiogenesis Inhibitors Product and Services

Table 163. Fresenius Kabi Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 164. Fresenius Kabi Recent Developments/Updates

Table 165. Fresenius Kabi Competitive Strengths & Weaknesses

Table 166. Celltrion Basic Information, Manufacturing Base and Competitors
Table 167. Celltrion Major Business
Table 168. Celltrion Cancer Angiogenesis Inhibitors Product and Services
Table 169. Celltrion Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 170. Celltrion Recent Developments/Updates
Table 171. Celltrion Competitive Strengths & Weaknesses
Table 172. Samsung Bioepis Basic Information, Manufacturing Base and Competitors
Table 173. Samsung Bioepis Major Business
Table 174. Samsung Bioepis Cancer Angiogenesis Inhibitors Product and Services
Table 175. Samsung Bioepis Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 176. Samsung Bioepis Recent Developments/Updates
Table 177. Samsung Bioepis Competitive Strengths & Weaknesses
Table 178. Biocon Biologics Basic Information, Manufacturing Base and Competitors
Table 179. Biocon Biologics Major Business
Table 180. Biocon Biologics Cancer Angiogenesis Inhibitors Product and Services
Table 181. Biocon Biologics Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 182. Biocon Biologics Recent Developments/Updates
Table 183. Biocon Biologics Competitive Strengths & Weaknesses
Table 184. Amneal Basic Information, Manufacturing Base and Competitors
Table 185. Amneal Major Business
Table 186. Amneal Cancer Angiogenesis Inhibitors Product and Services
Table 187. Amneal Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 188. Amneal Recent Developments/Updates
Table 189. Amneal Competitive Strengths & Weaknesses
Table 190. Dr. Reddy's Basic Information, Manufacturing Base and Competitors
Table 191. Dr. Reddy's Major Business
Table 192. Dr. Reddy's Cancer Angiogenesis Inhibitors Product and Services
Table 193. Dr. Reddy's Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 194. Dr. Reddy's Recent Developments/Updates

Table 195. Dr. Reddy's Competitive Strengths & Weaknesses

Table 196. Intas Pharmaceuticals Basic Information, Manufacturing Base and Competitors

Table 197. Intas Pharmaceuticals Major Business

Table 198. Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Product and Services

Table 199. Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 200. Intas Pharmaceuticals Recent Developments/Updates

Table 201. Intas Pharmaceuticals Competitive Strengths & Weaknesses

Table 202. Hetero Drugs Basic Information, Manufacturing Base and Competitors

Table 203. Hetero Drugs Major Business

Table 204. Hetero Drugs Cancer Angiogenesis Inhibitors Product and Services

Table 205. Hetero Drugs Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 206. Hetero Drugs Recent Developments/Updates

Table 207. Hetero Drugs Competitive Strengths & Weaknesses

Table 208. Zydus Lifesciences Basic Information, Manufacturing Base and Competitors

Table 209. Zydus Lifesciences Major Business

Table 210. Zydus Lifesciences Cancer Angiogenesis Inhibitors Product and Services

Table 211. Zydus Lifesciences Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 212. Zydus Lifesciences Recent Developments/Updates

Table 213. Zydus Lifesciences Competitive Strengths & Weaknesses

Table 214. Reliance Life Sciences Basic Information, Manufacturing Base and Competitors

Table 215. Reliance Life Sciences Major Business

Table 216. Reliance Life Sciences Cancer Angiogenesis Inhibitors Product and Services

Table 217. Reliance Life Sciences Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 218. Reliance Life Sciences Recent Developments/Updates

Table 219. Reliance Life Sciences Competitive Strengths & Weaknesses

Table 220. FUJIFILM Kyowa Kirin Biologics Basic Information, Manufacturing Base and Competitors

Table 221. FUJIFILM Kyowa Kirin Biologics Major Business

Table 222. FUJIFILM Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Product and Services

Table 223. FUJIFILM Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 224. FUJIFILM Kyowa Kirin Biologics Recent Developments/Updates

Table 225. FUJIFILM Kyowa Kirin Biologics Competitive Strengths & Weaknesses

Table 226. Innovent Biologics Basic Information, Manufacturing Base and Competitors

Table 227. Innovent Biologics Major Business

Table 228. Innovent Biologics Cancer Angiogenesis Inhibitors Product and Services

Table 229. Innovent Biologics Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 230. Innovent Biologics Recent Developments/Updates

Table 231. Innovent Biologics Competitive Strengths & Weaknesses

Table 232. Shanghai Henlius Basic Information, Manufacturing Base and Competitors

Table 233. Shanghai Henlius Major Business

Table 234. Shanghai Henlius Cancer Angiogenesis Inhibitors Product and Services

Table 235. Shanghai Henlius Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 236. Shanghai Henlius Recent Developments/Updates

Table 237. Shanghai Henlius Competitive Strengths & Weaknesses

Table 238. Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors

Table 239. Qilu Pharmaceutical Major Business

Table 240. Qilu Pharmaceutical Cancer Angiogenesis Inhibitors Product and Services

Table 241. Qilu Pharmaceutical Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 242. Qilu Pharmaceutical Recent Developments/Updates

Table 243. Qilu Pharmaceutical Competitive Strengths & Weaknesses

Table 244. Jiangsu Hengrui Medicine Basic Information, Manufacturing Base and Competitors

Table 245. Jiangsu Hengrui Medicine Major Business

Table 246. Jiangsu Hengrui Medicine Cancer Angiogenesis Inhibitors Product and Services

Table 247. Jiangsu Hengrui Medicine Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market

Share (2021-2026)

Table 248. Jiangsu Hengrui Medicine Recent Developments/Updates

Table 249. Jiangsu Hengrui Medicine Competitive Strengths & Weaknesses

Table 250. Akeso Basic Information, Manufacturing Base and Competitors

Table 251. Akeso Major Business

Table 252. Akeso Cancer Angiogenesis Inhibitors Product and Services

Table 253. Akeso Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 254. Akeso Recent Developments/Updates

Table 255. Akeso Competitive Strengths & Weaknesses

Table 256. Bio-Thera Solutions Basic Information, Manufacturing Base and Competitors

Table 257. Bio-Thera Solutions Major Business

Table 258. Bio-Thera Solutions Cancer Angiogenesis Inhibitors Product and Services

Table 259. Bio-Thera Solutions Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 260. Bio-Thera Solutions Recent Developments/Updates

Table 261. Bio-Thera Solutions Competitive Strengths & Weaknesses

Table 262. Chia Tai Tianqing Pharmaceutical Basic Information, Manufacturing Base and Competitors

Table 263. Chia Tai Tianqing Pharmaceutical Major Business

Table 264. Chia Tai Tianqing Pharmaceutical Cancer Angiogenesis Inhibitors Product and Services

Table 265. Chia Tai Tianqing Pharmaceutical Cancer Angiogenesis Inhibitors Production (K Dose), Price (US\$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 266. Chia Tai Tianqing Pharmaceutical Recent Developments/Updates

Table 267. Chia Tai Tianqing Pharmaceutical Competitive Strengths & Weaknesses

Table 268. Global Key Players of Cancer Angiogenesis Inhibitors Upstream (Raw Materials)

Table 269. Global Cancer Angiogenesis Inhibitors Typical Customers

Table 270. Cancer Angiogenesis Inhibitors Typical Distributors

List Of Figures

LIST OF FIGURES

Figure 1. Cancer Angiogenesis Inhibitors Picture

Figure 2. World Cancer Angiogenesis Inhibitors Production Value: 2021 & 2025 & 2032, (USD Million)

Figure 3. World Cancer Angiogenesis Inhibitors Production Value and Forecast (2021-2032) & (USD Million)

Figure 4. World Cancer Angiogenesis Inhibitors Production (2021-2032) & (K Dose)

Figure 5. World Cancer Angiogenesis Inhibitors Average Price (2021-2032) & (US\$/Dose)

Figure 6. World Cancer Angiogenesis Inhibitors Production Value Market Share by Region (2021-2032)

Figure 7. World Cancer Angiogenesis Inhibitors Production Market Share by Region (2021-2032)

Figure 8. North America Cancer Angiogenesis Inhibitors Production (2021-2032) & (K Dose)

Figure 9. Europe Cancer Angiogenesis Inhibitors Production (2021-2032) & (K Dose)

Figure 10. China Cancer Angiogenesis Inhibitors Production (2021-2032) & (K Dose)

Figure 11. Japan Cancer Angiogenesis Inhibitors Production (2021-2032) & (K Dose)

Figure 12. India Cancer Angiogenesis Inhibitors Production (2021-2032) & (K Dose)

Figure 13. South Korea Cancer Angiogenesis Inhibitors Production (2021-2032) & (K Dose)

Figure 14. Cancer Angiogenesis Inhibitors Market Drivers

Figure 15. Factors Affecting Demand

Figure 16. World Cancer Angiogenesis Inhibitors Consumption (2021-2032) & (K Dose)

Figure 17. World Cancer Angiogenesis Inhibitors Consumption Market Share by Region (2021-2032)

Figure 18. United States Cancer Angiogenesis Inhibitors Consumption (2021-2032) & (K Dose)

Figure 19. China Cancer Angiogenesis Inhibitors Consumption (2021-2032) & (K Dose)

Figure 20. Europe Cancer Angiogenesis Inhibitors Consumption (2021-2032) & (K Dose)

Figure 21. Japan Cancer Angiogenesis Inhibitors Consumption (2021-2032) & (K Dose)

Figure 22. South Korea Cancer Angiogenesis Inhibitors Consumption (2021-2032) & (K Dose)

Figure 23. ASEAN Cancer Angiogenesis Inhibitors Consumption (2021-2032) & (K Dose)

Figure 24. India Cancer Angiogenesis Inhibitors Consumption (2021-2032) & (K Dose)

Figure 25. Producer Shipments of Cancer Angiogenesis Inhibitors by Manufacturer Revenue (\$MM) and Market Share (%): 2025

Figure 26. Global Four-firm Concentration Ratios (CR4) for Cancer Angiogenesis Inhibitors Markets in 2025

Figure 27. Global Four-firm Concentration Ratios (CR8) for Cancer Angiogenesis Inhibitors Markets in 2025

Figure 28. United States VS China: Cancer Angiogenesis Inhibitors Production Value Market Share Comparison (2021 & 2025 & 2032)

Figure 29. United States VS China: Cancer Angiogenesis Inhibitors Production Market Share Comparison (2021 & 2025 & 2032)

Figure 30. United States VS China: Cancer Angiogenesis Inhibitors Consumption Market Share Comparison (2021 & 2025 & 2032)

Figure 31. United States Based Manufacturers Cancer Angiogenesis Inhibitors Production Market Share 2025

Figure 32. China Based Manufacturers Cancer Angiogenesis Inhibitors Production Market Share 2025

Figure 33. Rest of World Based Manufacturers Cancer Angiogenesis Inhibitors Production Market Share 2025

Figure 34. World Cancer Angiogenesis Inhibitors Production Value by Type, (USD Million), 2021 & 2025 & 2032

Figure 35. World Cancer Angiogenesis Inhibitors Production Value Market Share by Type in 2025

Figure 36. VEGF-targeted Therapy

Figure 37. FGF-targeted Therapy

Figure 38. Oncogene-targeted Therapy

Figure 39. Matrix Degradation and Remodeling-targeted Therapy

Figure 40. Others

Figure 41. World Cancer Angiogenesis Inhibitors Production Market Share by Type (2021-2032)

Figure 42. World Cancer Angiogenesis Inhibitors Production Value Market Share by Type (2021-2032)

Figure 43. World Cancer Angiogenesis Inhibitors Average Price by Type (2021-2032) & (US\$/Dose)

Figure 44. World Cancer Angiogenesis Inhibitors Production Value by Product Origin, (USD Million), 2021 & 2025 & 2032

Figure 45. World Cancer Angiogenesis Inhibitors Production Value Market Share by Product Origin in 2025

Figure 46. Originator Biologics

Figure 47. Generic Drugs

Figure 48. World Cancer Angiogenesis Inhibitors Production Market Share by Product Origin (2021-2032)

Figure 49. World Cancer Angiogenesis Inhibitors Production Value Market Share by Product Origin (2021-2032)

Figure 50. World Cancer Angiogenesis Inhibitors Average Price by Product Origin (2021-2032) & (US\$/Dose)

Figure 51. World Cancer Angiogenesis Inhibitors Production Value by Route of Administration, (USD Million), 2021 & 2025 & 2032

Figure 52. World Cancer Angiogenesis Inhibitors Production Value Market Share by Route of Administration in 2025

Figure 53. Intravenous Infusion

Figure 54. Oral Administration

Figure 55. Others

Figure 56. World Cancer Angiogenesis Inhibitors Production Market Share by Route of Administration (2021-2032)

Figure 57. World Cancer Angiogenesis Inhibitors Production Value Market Share by Route of Administration (2021-2032)

Figure 58. World Cancer Angiogenesis Inhibitors Average Price by Route of Administration (2021-2032) & (US\$/Dose)

Figure 59. World Cancer Angiogenesis Inhibitors Production Value by Target Breadth, (USD Million), 2021 & 2025 & 2032

Figure 60. World Cancer Angiogenesis Inhibitors Production Value Market Share by Target Breadth in 2025

Figure 61. Single-target Agents

Figure 62. Dual-target Agents

Figure 63. Multi-target Agents

Figure 64. Others

Figure 65. World Cancer Angiogenesis Inhibitors Production Market Share by Target Breadth (2021-2032)

Figure 66. World Cancer Angiogenesis Inhibitors Production Value Market Share by Target Breadth (2021-2032)

Figure 67. World Cancer Angiogenesis Inhibitors Average Price by Target Breadth (2021-2032) & (US\$/Dose)

Figure 68. World Cancer Angiogenesis Inhibitors Production Value by Application, (USD Million), 2021 & 2025 & 2032

Figure 69. World Cancer Angiogenesis Inhibitors Production Value Market Share by Application in 2025

Figure 70. Cancer

Figure 71. Interferon Alpha-2?

Figure 72. Ocular Neovascularization

Figure 73. World Cancer Angiogenesis Inhibitors Production Market Share by Application (2021-2032)

Figure 74. World Cancer Angiogenesis Inhibitors Production Value Market Share by Application (2021-2032)

Figure 75. World Cancer Angiogenesis Inhibitors Average Price by Application (2021-2032) & (US\$/Dose)

Figure 76. Cancer Angiogenesis Inhibitors Industry Chain

Figure 77. Cancer Angiogenesis Inhibitors Procurement Model

Figure 78. Cancer Angiogenesis Inhibitors Sales Model

Figure 79. Cancer Angiogenesis Inhibitors Sales Channels, Direct Sales, and Distribution

Figure 80. Methodology

Figure 81. Research Process and Data Source

I would like to order

Product name: Global Cancer Angiogenesis Inhibitors Supply, Demand and Key Producers, 2026-2032

Product link: <https://marketpublishers.com/r/G552C89D1871EN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G552C89D1871EN.html>